Sherman's 1400 Broadway, N.Y.C. LLC.
Letter data
- Company
- Sherman's 1400 Broadway, N.Y.C. LLC.
- Recipient
- Sherman's 1400 Broadway, N.Y.C. LLC. | United States
- Issue date
- 2018-02-23
- Posted date
- Not available
- FDA office
- United States
- Subject
- Not available
- Product
- Not available
- CMS ID
- 475207
- Reference number
- Not available
- FEI
- Not available
- Inspection dates
- Not available
Normalized citations
21 CFR: None found
21 U.S.C.: None found
Related FDA links
No related FDA letter link is present in the source index.
Full source text
CLOSEOUT LETTER
Sherman's 1400 Broadway, N.Y.C. LLC.
MARCS-CMS 475207 —
February 23, 2018
More Warning Letters
Warning Letters
About Warning and Close-Out Letters
Recipient:
Sherman's 1400 Broadway, N.Y.C. LLC.
United States
Issuing Office:
United States
Center for Tobacco Products
10903 New Hampshire Avenue
Silver Spring, MD 20993
FEB 23, 2018
VIA UPS
William M. Sherman
Executive Vice President
Sherman's 1400 Broadway N.Y.C., Ltd.
10 Sterling Blvd.
3rd Floor
Englewood, NJ 07631
RE: Warning Letter issued to Sherman's 1400 Broadway N.Y.C. LLC (Nat Sherman) (RW1500346)
Dear Mr. Sherman:
On August 27, 2015, the United States Food and Drug Administration's (FDA) Center for Tobacco Products (CTP) issued you a Warning Letter for the sale or distribution of modified risk tobacco products without an FDA order in effect that permits such sale or distribution, in violation of section 911 of the Federal Food, Drug, and Cosmetic Act (FD&C Act). Specifically, you sold or distributed Nat Sherman cigarette products described in product labeling as "Natural."
In response to the Warning Letter, you stated that you implemented corrective actions to address the violations identified in the Warning Letter. You also submitted revised labeling and advertising for your products pursuant to section 905(i) of the Federal Food, Drug, and Cosmetic Act.
FDA conducted an inspection of your manufacturing facility to confirm your corrective actions. After reviewing the results of this inspection, it appears that you have addressed the violations identified in the Warning Letter.
This letter does not relieve you or your firm from the responsibility of taking all necessary steps to ensure sustained compliance with the FD&C Act and its implementing regulations or with other relevant legal authority. This letter also will not preclude any regulatory action should violations be observed in the future.
Sincerely,
/S/
Ele Ibarra-Pratt
Director
Division of Promotion, Advertising and Labeling
Office of Compliance and Enforcement
Center for Tobacco Products
Content current as of:
02/28/2018